The novel coronavirus (SARS-CoV-2) omicron mutation, first discovered in South Africa in November last year, began to spread rapidly around the world from the beginning of this year.
Omicron spread much faster than the original novel coronavirus and caused more breakthrough infections than any other mutation that had appeared before. The same is true for those who have developed immunity from natural infection, or those who have been fully vaccinated, and those who have been pierced by Omicron.
Where does this powerful radio wave of Omicron come from?
Corona mutations before Omicron had many mutations in the spike protein.
However, in the case of Omicron, research results have shown that mutations in the nucleocapsid are the source of strong transmission and immune evasion.
The results of this study conducted jointly by scientists at the Gladstone Institute and the University of California, Berkeley (UC Berkeley) were published as a paper in the Proceedings of the National Academy of Sciences (PNAS) on the 19th.
The co-lead author of the paper, Dr. Melanie Ott of the Gladstone Institute and Professor Jennifer Doudna of UC Berkeley, said that the propagation power of a similar virus with a mutation such as omicron in the spike protein is the same as when a mutation in the spike protein of a lineage upstream mutation occurs. I’m hungry. However, when a mutation such as Omicron occurs, the infectious power is increased by a whopping 30 times.
The neutralizing ability of the antibody was relatively strong in those vaccinated with mRNA. However, mRNA vaccines were also found to be insufficient to prevent delta mutations or omicron mutations.
Plasma from humans 4 to 6 weeks after receiving the mRNA vaccine (38 people in the experimental group size) showed a relatively high neutralizing ability against the ‘ancestral mutation’ (a similar virus) that preceded Omicron. However, the neutralizing ability of the antibody fell to 1/3 for the delta mutation and 1/15 for the omicron. Plasma from those vaccinated with the Johnson & Johnson vaccine or recovered from spontaneous infection showed a lower neutralizing ability than the mRNA vaccine for ‘ancestral mutations’, and there was little difference for delta and omicron mutations. In addition, in the eight subjects who received the Pfizer third-line vaccine two to three weeks later, there were detectable neutralizing antibodies against all mutations.
However, the level of antibodies neutralizing Omicron was only one-eighth of that of other mutated neutralizing antibodies. This means that it is difficult to prevent Omicron mutations with existing coronavirus vaccines, regardless of manufacturer and type.
